The landscape of metabolic health shifted significantly as the US FDA granted Breakthrough Therapy Designation to efimosfermin, a once-monthly investigational liver therapy targeting Metabolic Dysfunction-Associated Steatohepatitis (MASH) (My, 2026).
Concurrently, the European Medicines Agency awarded the drug PRIME status (My, 2026). Phase II data revealed that the subcutaneous...
